GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Asset Turnover

New Ray Medicine International Holding (HKSE:06108) Asset Turnover : -0.05 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. New Ray Medicine International Holding's Revenue for the six months ended in Dec. 2023 was HK$-22.89 Mil. New Ray Medicine International Holding's Total Assets for the quarter that ended in Dec. 2023 was HK$509.43 Mil. Therefore, New Ray Medicine International Holding's Asset Turnover for the quarter that ended in Dec. 2023 was -0.05.

Asset Turnover is linked to ROE % through Du Pont Formula. New Ray Medicine International Holding's annualized ROE % for the quarter that ended in Dec. 2023 was -3.62%. It is also linked to ROA % through Du Pont Formula. New Ray Medicine International Holding's annualized ROA % for the quarter that ended in Dec. 2023 was -3.46%.


New Ray Medicine International Holding Asset Turnover Historical Data

The historical data trend for New Ray Medicine International Holding's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Asset Turnover Chart

New Ray Medicine International Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.20 0.51 0.15 0.10

New Ray Medicine International Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.09 0.05 0.14 -0.05

Competitive Comparison of New Ray Medicine International Holding's Asset Turnover

For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


New Ray Medicine International Holding's Asset Turnover Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Asset Turnover distribution charts can be found below:

* The bar in red indicates where New Ray Medicine International Holding's Asset Turnover falls into.



New Ray Medicine International Holding Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

New Ray Medicine International Holding's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=50.154/( (539.849+491.603)/ 2 )
=50.154/515.726
=0.10

New Ray Medicine International Holding's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-22.885/( (527.252+491.603)/ 2 )
=-22.885/509.4275
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


New Ray Medicine International Holding  (HKSE:06108) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

New Ray Medicine International Holding's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-17.626/487.317
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-17.626 / -45.77)*(-45.77 / 509.4275)*(509.4275/ 487.317)
=Net Margin %*Asset Turnover*Equity Multiplier
=38.51 %*-0.0898*1.0454
=ROA %*Equity Multiplier
=-3.46 %*1.0454
=-3.62 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

New Ray Medicine International Holding's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-17.626/509.4275
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-17.626 / -45.77)*(-45.77 / 509.4275)
=Net Margin %*Asset Turnover
=38.51 %*-0.0898
=-3.46 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


New Ray Medicine International Holding Asset Turnover Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines